

Bloom Burton & Co.
Healthcare Investor Conference
May 2 - 3, 2016

OUR SPONSORS

We gratefully acknowledge the support of our sponsors

GOLD SPONSORS



BAKER & MCKENZIE



BDO



Blakes



EY
Building a better
working world



JLT



Johnson & Johnson INNOVATION
— JLABS —



mccarthy
tétrault



N|A|T|I|O|N|A|L | Equicom



The Horwood Team



RICHARDSON GMP



TRINITY
Underwriting



TROUTMAN
SANDERS

SILVER SPONSOR



TMX | Toronto Stock Exchange | TSX Venture Exchange | TSX Private Markets

Welcome to the 2016 Bloom Burton & Co. Healthcare Investor Conference

Bloom Burton exists to accelerate returns in healthcare and there is no better illustration of that than this very conference, which brings together hundreds of entrepreneurs and investors to meet, learn and plan for growth.

This has been a year of growth and growing pains for the Canadian healthcare sector. We have seen robust financing and corporate activity, and the deployment of significant venture, private and public market capital, yet we also experienced a challenging specialty pharmaceutical market where drug pricing, debt ratios and tax-driven M&A remain front page news. Additionally, a volatile and weakening Canadian exchange rate, decreasing earnings and other negative macroeconomic events changed investors' risk appetite, which has contributed to mixed or negative returns. We are certainly in a "stock picker's" market, in which individual companies can certainly succeed, despite the uncertain macro environment. This conference is a great place for you to uncover winners.

Bloom Burton continues to grow. We have expanded the number of professionals at our firm and we have served even more companies and investor clients through our investment banking, research and consulting work. We also grew our asset management affiliate firm with the launch of the Bloom Burton Healthcare Lending Trust. Finally, the exciting companies we have created and incubated, including Triumvira Immunologics, Appili Therapeutics and Grey Wolf Animal Health, will be coming out of stealth mode and presenting at the conference.

We are honoured to serve this noble industry and so proud of our talented team, who work with such dedication to serve our clients. We strive to produce exceptional deliverables and outcomes and we are here for you as you meet and plan for the success of the healthcare sector in Canada.

Have a wonderful conference!

Brian and Jolyon



Network: SHERATON_MEETINGS
Password: bloomburton2016

Corporate presentations will be available via a weblink to be emailed to attendees after the conference.

AGENDA - DAY 1

8:30

Welcome and introductory remarks

8:45

KEYNOTE

Luke Timmerman, *Founder & Editor of the Timmerman Report*

OSGOODE BALLROOM

9:30

HALL C

HALL B

HALL A

Cardiome
Pharma

ESSA
Pharma

TSO₃

10:00

CRH Medical

Cynapsus
Therapeutics

Titan Medical

10:30

Nobilis Health

Bellus
Health

LED Medical
Diagnostics

11:00

Therapure
Biopharma

Aurinia
Pharmaceuticals

Covalon
Technologies

11:30

Aralez
Pharmaceuticals

Resverlogix

Profound
Medical

12:00

Lunch

12:30

PANEL

Venture Capital Investor Panel, *Moderated by Brian Bloom*

OSGOODE BALLROOM

13:30

HALL C

HALL B

HALL A

Knight
Therapeutics

VBI Vaccines

Synaptive
Medical

14:00

Nuvo
Pharmaceuticals

Aptose
Biosciences

Conavi
Medical

14:30

Pharmascience

Antibe
Therapeutics

Klox
Technologies

15:00

Merus Labs

Aequus
Pharmaceuticals

VanRx
PharmaSystems

15:30

NuGeneris

IntelGenx

CellAegis
Devices

16:00

Acerus
Pharmaceuticals

Oncolytics
Biotech

Interface
Biologics

17:00

Reception
Osgoode Ballroom

8:30



Breakfast and Panel

PANEL

Public Market Investor Panel, *Moderated by Brian Bloom*

OSGOODE BALLROOM

9:30

HALL C

Zymeworks

HALL B

HLS
Therapeutics

HALL A

LEAGUE

10:00

Clementia
Pharmaceuticals

Cipher
Pharmaceuticals

Newtopia

10:30

Arbutus
Biopharma

BioSyent

Think
Research

11:00

Trillium
Therapeutics

Theratechnologies

CannTrust

11:30

Aquinox
Pharmaceuticals

Medicure

Triumvira
Immunologies

12:00



Lunch

12:30

KEYNOTE

Scott Gottlieb, *Resident Fellow, American Enterprise Institute*

OSGOODE BALLROOM

13:30

HALL C

ProMetic Life
Sciences

HALL B

Novadaq
Technologies

HALL A

Appili
Therapeutics

14:00

Medicago

Pediapharm

Medicenna
Therapeutics

14:30

Xenon
Pharmaceuticals

Searchlight
Pharma

Turnstone
Biologics

15:00

Immunovaccine

Hamilton Thorne

Induce
Biologics

15:30

Avivagen

INTEGA Skin
Sciences

Parvus
Therapeutics

16:00

Sophiris Bio

Grey Wolf
Animal Health

SequenceBio



Thank you for attending!



Acerus Pharmaceuticals

DAY 1 - May 2, 2016
16:00
Hall C

TSX: ASP

Acerus Pharmaceuticals Corporation is a Canadian pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve the patient experience. Acerus markets ESTRACE® in Canada, a product indicated for the symptomatic relief of menopausal symptoms. NATESTO™, a product utilizing an Acerus licensed nasal gel technology, is the first and only testosterone nasal gel approved in Canada, and available in the United States for replacement therapy in adult males diagnosed with hypogonadism. GYNOFLOR™, a product licensed to Acerus in Canada by Medinova AG, is an ultra-low dose vaginal estrogen therapy with the addition of lactobacillus, for the treatment of atrophic vaginitis, certain vaginal infections and to restore a healthy vaginal environment. TEFINA™, a 'use as required' nasal testosterone gel, is an Acerus drug development candidate aimed at addressing a significant unmet need for women with female sexual dysfunction.



Aequus Pharmaceuticals

DAY 1 - May 2, 2016
15:00
Hall B

TSX-V: AQS, OTCQB: AQSZF

Aequus Pharmaceuticals Inc. is a rapidly growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus' sales and marketing efforts are based in Canada, targeting highly specialized therapeutic areas including neurology, ophthalmology and transplant. Aequus is developing a pipeline of products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. Aequus intends to commercialize its internal programs in Canada and to establish strategic partnerships to accelerate and maximize the potential of its product candidates worldwide. Aequus intends on building this Canadian commercial platform with the launch of additional products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas.



Antibe Therapeutics

DAY 1 - May 2, 2016
14:30
Hall B

TSX-V:ATE; OTCQX:ATBPF

Antibe develops safer medicines for pain and inflammation. Antibe's technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe's lead drug ATB-346 targets the global need for a safer non-steroidal anti-inflammatory drug (NSAID) for chronic pain and inflammation. ATB-352, the second drug in Antibe's pipeline, targets the urgent global need for a safer analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin.



Appili Therapeutics

DAY 2 - May 3, 2016
13:30
Hall A

Private

Appili is dedicated to identifying, acquiring and advancing novel therapeutics in the area of infectious disease and has commenced development on two anti-infective programs, while continuing its search to acquire additional high quality anti-infective programs at all stages of development. The company plans to take its lead drug candidate, ATI-1501, a potential treatment for *C. difficile* infection, into clinical trials by 2017. Appili's second product, ATI-1503, is a novel antibiotic with the potential to treat deadly infections such as *Klebsiella pneumoniae*. These drug-resistant Gram-negative bacterial infections have been identified by the U.S. Center for Disease Control (CDC) as posing the highest threat to human health. Appili was co-founded by Bloom Burton & Co.



Aptose Biosciences

DAY 1 - May 2, 2016
14:00
Hall B

TSX: APS, NASDAQ: APTO

Aptose Biosciences is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer research coupled with companion diagnostics to identify the optimal patient population for our products. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.



Aquinox Pharmaceuticals

DAY 2 - May 3, 2016
11:30
Hall C

NASDAQ: AQXP

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. With a successful Phase 2 clinical trial completed in 2015, Aquinox plans to initiate a Phase 3 trial in 2016 with AQX-1125 for treatment of interstitial cystitis/bladder pain syndrome (IC/BPS). Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1.



Aralez Pharmaceuticals

DAY 1 - May 2, 2016
11:30
Hall C

TSX: ARZ, NASDAQ: ARLZ

Aralez Pharmaceuticals Inc. is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients' lives while focusing on creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular, pain and other specialty areas. Aralez's Global Headquarters is in Ontario, Canada, the US Headquarters is planned to be in Princeton, NJ and the Irish Headquarters is in Dublin, Ireland. The combination of POZEN Inc. and Tribute Pharmaceuticals Canada Inc. represents an important strategic transformation that created Aralez, a specialty pharmaceutical company with a compelling growth platform, from which we believe we can drive significant long-term value creation.



Arbutus Biopharma

DAY 2 - May 3, 2016
10:30
Hall C

NASDAQ: ABUS

Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Our strategy is to target the three pillars necessary to develop a curative regimen for HBV: suppressing HBV replication within liver cells, stimulating and reactivating the body's immune system so that it can mount an effective defense against the virus and, eliminating the reservoir of viral genomic material known as covalently closed circular DNA, or cccDNA that is the source of HBV persistence. Our portfolio of assets includes a broad pipeline of drug candidates for use in combination to develop a cure for HBV. To support continuous discovery of potential novel drug candidates and technologies, Arbutus has a research collaboration agreement with the Baruch S. Blumberg Institute that provides exclusive rights to in-license any intellectual property generated through the relationship. The Baruch S. Blumberg Institute was established in 2003 by the Hepatitis B Foundation.



Aurinia Pharmaceuticals

DAY 1 - May 2, 2016
11:00
Hall B

TSX:AUP, NASDAQ:AUPH

Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. The fully-enrolled Phase 2b AURA-LV clinical trial is evaluating the efficacy of its lead drug, voclosporin, as a treatment for active LN. LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal disease, making LN a serious and potentially life-threatening condition. Voclosporin is a novel and potentially best-in-class calcineurin inhibitor ("CNI") with extensive clinical data in over 2,000 patients in other indications. Voclosporin is made by a modification of a single amino acid of the cyclosporine molecule (a CNI approved for use in transplant patients since 1983). This modification results in a more predictable pharmacokinetic and pharmacodynamic relationship, an increase in potency vs. cyclosporine, an altered metabolic profile, and potential for flat dosing.



Avivagen

DAY 2 - May 3, 2016
15:30
Hall C

TSX-V: VIV

Avivagen Inc. is a publicly-listed life sciences company developing scientifically-proven products for replacing antibiotics in livestock feeds and to benefit human and animal health. Its target markets include enhancing productivity and health in livestock, companion animal quality-of-life, and maintaining optimal health in humans. Avivagen's proprietary and patented technology derives from its discovery that carotenoid oxidation produces oxygen copolymer products that have beneficial immunological properties. Avivagen's commercial-stage application of its inventions is fully oxidized beta-carotene ("OxBC"), OxC-beta™ Technology ("OxC-beta"). Avivagen has discovered that OxC-beta can help an animal's own systems to maintain and enhance health by supporting immune function and calming excess inflammation. Avivagen is developing OxC-beta to replace the antibiotics used for disease prevention and growth promotion in livestock feeds, to enhance quality of life of companion animals and to help maintain optimal health in humans. Avivagen's commercial products are OxC-beta™ Livestock (Kingdom of Thailand), Vivamune™ Vital Health3 Chews (U.S.) and Oximuno!™ Chewable Tablets (U.S.).



Bellus Health

DAY 1 - May 2, 2016
10:30
Hall B

TSX : BLU

BELLUS Health is a drug development company focused on rare diseases. Its pipeline of rare disease projects includes KIACTA™ in Phase 3 for AA amyloidosis, KIACTA™ for sarcoidosis, clinical stage Shigamab™ for sHUS and a research-stage project for AL amyloidosis. The lead program KIACTA™ is currently in a Phase 3 Confirmatory Study for the treatment of AA amyloidosis, an orphan indication resulting in renal dysfunction that often leads to dialysis and death. BELLUS Health is partnered with global private equity firm Auen Therapeutics for the development of KIACTA™.



BioSyent

DAY 2 - May 3, 2016
10:30
Hall B

TSX-V: RX

BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units.



CannTrust

DAY 2 - May 3, 2016
11:00
Hall A

Private

CannTrust received its license to produce medical cannabis for patients in June 2014. Based in Vaughan, Ontario, CannTrust is committed to producing the highest quality pharmaceutical grade cannabis; promoting evidence based clinical research; and providing exceptional customer support. CannTrust has invested in its state-of-art hydroponic facility and onsite laboratory equipped with leading-edge technology, and has an exceptional team of pharmacists, nurses, scientists, laboratory technicians, master growers and call centre specialists. With patient access as the focus, the company provides the most comprehensive Patient Assistance Program for patients with financial needs in Canada. In addition, CannTrust places an emphasis on patient education and the elimination of social barriers through numerous initiatives and partnerships.



Cardiome Pharma

DAY 1 - May 2, 2016
9:30
Hall C

TSX: COM, NASDAQ: CRME

Cardiome Pharma Corp. is a specialty pharmaceutical company dedicated to the development and commercialization of cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. Cardiome has two marketed, in-hospital, cardiology products, BRINAVESS® (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults, and AGGRASTAT® (tirofiban HCl) a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome. Cardiome also commercializes Esmocard® and Esmocard Lyo® (esmolol hydrochloride), a short-acting beta-blocker used to control rapid heart rate in a number of cardiovascular indications, on behalf of their partner AOP Orphan Pharma in select European markets. Cardiome has also licensed TREVYENT®, a development stage drug device combination that is under development for Pulmonary Arterial Hypertension for Europe, the Middle East and for Canadian markets.



CellAegis

DAY 1 - May 2, 2016

15:30

Hall A

Private

CellAegis Devices, Inc., based in Toronto, Canada, is poised for EU market introduction in parallel with a broad international clinical testing program of the Company's proprietary, automated, noninvasive autoRIC™ Device for Remote Ischemic Conditioning (RIC). Placed around the arm, CellAegis' autoRIC Device allows for the first time, simple, consistent, reliable and cost-effective automation of RIC at the point of care, including acute care applications in the ambulance, emergency room and other hospital settings, or for chronic treatment in the home. The autoRIC Device is highly portable and time-efficient, delivering four cycles of simple-to-administer treatment in less than 40 minutes. The device is compatible with current standard-of-care treatments. CellAegis has extensive intellectual property protections for its autoRIC Device. In late 2011, CellAegis received ISO 13485 certification which covers the design, development, manufacturing and distribution of medical devices.



Cipher Pharmaceuticals

DAY 2 - May 3, 2016

10:00

Hall B

TSX: CPH, NASDAQ: CPHR

Cipher Pharmaceuticals is a rapidly growing specialty pharmaceutical dermatology company with a diversified portfolio of commercial-stage products with the goal of becoming the most customer-centric dermatology company in North America. Cipher completed seven transactions in 2015, including the acquisition of Innocutis and its nine branded dermatology products, to build its U.S. commercial presence, expand its Canadian dermatology franchise and broaden its pipeline. Cipher is well-capitalized to drive long-term, sustained earnings growth by leveraging its proven clinical development capabilities and efficient commercial execution.



Clementia Pharmaceuticals

DAY 2 - May 3, 2016
10:00
Hall C

Private

Clementia is a clinical stage biopharmaceutical company committed to delivering treatments to people who have none. The company is developing its lead candidate palovarotene, a novel retinoic acid receptor gamma agonist, to treat fibrodysplasia ossificans progressiva (FOP) and other diseases. Palovarotene is a retinoic acid receptor gamma agonist being investigated as a treatment for FOP. Preclinical studies demonstrated that palovarotene blocked both injury-induced and spontaneous heterotopic ossification, maintained mobility, and restored skeletal growth in mouse models of FOP. Clementia licensed palovarotene from Roche Pharmaceuticals, which previously evaluated the compound in more than 800 subjects. Palovarotene received Fast Track designation from the U.S. Food and Drug Administration (FDA) and orphan designations for the treatment of FOP from both the FDA and the European Medicines Agency (EMA).



Conavi Medical

DAY 1 - May 2, 2016
14:00
Hall A

Private

Conavi Medical Inc. develops, manufactures, sells and supports technologies to help guide minimally invasive procedures. Our first product, the Foresight ICE System, is a catheter based ultrasound system which provides 2D and 3D images of the heart and devices in the heart during minimally invasive cardiovascular procedures such as Atrial Fibrillation Ablation. Our focus is on providing innovative image guidance technologies for minimally invasive procedures, with an initial emphasis on cardiovascular procedures. Conavi is commercializing technologies initially invented at Sunnybrook Research Institute in Toronto. Conavi employs over 35 highly qualified individuals at our 12,000 square foot ISO-13485 certified facility in Toronto.



covalon

Covalon Technologies

DAY 1 - May 2, 2016

11:00

Hall A

TSX-V: COV

Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility.



CYNAPSUS

Cynapsus Therapeutics

DAY 1 - May 2, 2016

10:00

Hall B

TSX: CTH, NASDAQ: CYNA

Cynapsus is a specialty central nervous system pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with PD. The Company has successfully completed a Phase 2 clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine. Apomorphine is the only molecule approved for acute, intermittent treatment of OFF episodes for advanced PD patients, but is currently only approved as a subcutaneous injection in the United States. APL-130277 is a "turning ON" medication designed to rapidly, safely and reliably convert a PD patient from the OFF to the ON state while avoiding many of the issues associated with subcutaneous delivery of apomorphine. It is designed to convert all types of OFF episodes, including morning OFF episodes, often considered the most difficult to treat. Cynapsus has initiated its Phase 3 clinical program for APL-130277, relying on the abbreviated Section 505(b)(2) regulatory pathway in the United States, and the Company intends to submit an NDA near the end of 2016 or in early 2017.



CRH Medical

DAY 1 - May 2, 2016
10:00
Hall C

TSX: CRH, NYSE MKT: CRHM

CRH Medical Corporation is a North American company focused on providing physicians with innovative products and services for the treatment of gastrointestinal diseases. The Company's first product, the CRH O'Regan System, is a single use, disposable, hemorrhoid banding technology that is safe and highly effective in treating hemorrhoid grades I - IV. In 2014, CRH acquired a full service gastroenterology anesthesia company, Gastroenterology Anesthesia Associates, LLC ("GAA"), which provides anesthesia services for patients undergoing endoscopic procedures and has complemented this acquisition with further acquisitions of anesthesia providers completed during the first, third and fourth quarters of 2015. The Company's goal is to establish CRH as the premier provider of innovative products and essential services to gastroenterologists throughout the United States.



ESSA Pharmaceuticals

DAY 1 - May 2, 2016
9:30
Hall B

TSX: EPI, NASDAQ: EPIX

ESSA Pharma is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of castration-resistant prostate cancer ("CRPC") in patients whose disease is progressing despite treatment with current therapies. ESSA believes that its product candidate, EPI-506, can significantly expand the interval of time in which patients suffering from CRPC can benefit from hormone-based therapies. EPI-506 acts by disrupting the androgen receptor ("AR") signaling pathway, which is the primary pathway that drives prostate cancer growth. We have shown that EPI-002, the primary metabolite of EPI-506, prevents AR activation by binding selectively to the N-terminal domain ("NTD") of the AR. A functional NTD is essential for activation of the AR. Blocking the NTD prevents activation of the AR by all of the three known mechanisms of activation. In pre-clinical studies, blocking the NTD has demonstrated the capability to overcome the known AR-dependent mechanisms of CRPC. ESSA was founded in 2009 and is located in Houston, Texas, and Vancouver, British Columbia.



Grey Wolf Animal Health

DAY 2 - May 3, 2016
16:00
Hall B

Private

Grey Wolf Animal Health is an emerging animal health specialty pharmaceutical startup. Grey Wolf's vision is to establish and grow itself as a fully integrated Canadian animal health company. Grey Wolf was founded by Canadian veterinarian Dr. Ian Sandler whose unique insights on market needs and gaps in Canada were gained over a two decade career in private practice. Grey Wolf plans to gain market share through careful selection of products that meets the needs of Canadian veterinarians and pet owners. Grey Wolf's three-pronged product commercialization strategy involves in-licensing/exclusive distribution partnerships with global animal health companies, product development via R&D, and acquisition of companies and assets of strategic value. Grey Wolf is expected to launch its first product offering in Q2 2016 and is on track to commercialize a portfolio of more than 25 products in five years with revenues of more than \$15M+. GWAH is headquartered in Toronto, Canada and is co-founded with Bloom Burton & Co.



Hamilton Thorne

DAY 2 - May 3, 2016
15:00
Hall B

TSX-V: HTL

Hamilton Thorne designs, manufactures and distributes precision laser devices and advanced imaging systems that reduce cost, increase productivity, improve results and enable breakthroughs in the assisted reproduction, regenerative medicine and developmental biology research markets. Hamilton Thorne's laser products attach to standard inverted microscopes and operate as robotic micro-surgeons, enabling a wide array of scientific applications and IVF procedures. Its imaging systems improve outcomes in human IVF clinics and animal breeding facilities and provide high-end toxicology analyses. Hamilton Thorne's growing worldwide customer base consists of pharmaceutical companies, biotechnology companies, fertility clinics, university research centers, animal breeding companies, and other commercial and academic research establishments, including Harvard, MIT, Yale, McGill, Oxford, Cambridge, the Smithsonian Institution, Charles River Labs, Covance, ABS Global, Sexing Technologies, Merck, Novartis, Pfizer, and Dow Chemical.



HLS Therapeutics Inc.

HLS Therapeutics

DAY 2 - May 3, 2016
9:30
Hall B

Private

Based in Toronto, and in its soon-to-be operational base in Montreal Quebec, HLS is dedicated to the stewardship of branded pharmaceuticals through their life cycles post-exclusivity, and promotional stage products in selected therapeutic areas. In August 2015, HLS completed the acquisition of the North American Canadian and US rights to CLOZARIL®. Management's focus is on commercial and legacy stage assets and driving growth in revenue, earnings and cash flow, not on scientific development and the associated regulatory risk.



Immunovaccine

DAY 2 - May 3, 2016
15:00
Hall C

TSX: IMV, OTCQX: IMMVF

Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company's DepoVax™ platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 2 study with its lead cancer vaccine therapy, DPX-Survivac, in recurrent lymphoma. DPX-Survivac is expected to enter additional Phase 2 clinical studies in ovarian cancer and glioblastoma (brain cancer). In collaboration with commercial and academic partners, Immunovaccine is also expanding the application of DepoVax™ as an adjuvanting platform for vaccines targeted against infectious diseases. Immunovaccine's goal in infectious diseases is to out-license its DepoVax™ platform to partners to generate earlier revenues.



Induce Biologics

DAY 2 - May 3 2016
15:00
Hall A

Private

Induce Biologics Inc. is a regenerative medicine company based in Toronto, Canada, that is developing bioimplants for bone regeneration. The lead product candidate, URIST™, is a novel implant that contains bone morphogenetic protein (BMP), and a proprietary carrier; this carrier provides a gradual, multi-phasic delivery of BMP. This gradual delivery allows for the use of less BMP compared to current products, making it more cost-effective. Also, since all known BMP adverse events and toxicity issues have been related to higher doses of BMP, the ability to use lower doses provides a potential risk benefit as well.



INTEGA Skin Sciences

DAY 2 - May 3, 2016
15:30
Hall B

Private

Founded in 2015, INTEGA Skin Sciences Inc. is a Montreal-based skincare company which aspires to become a benchmark in the pharmaceutical industry for the treatment and care of skin diseases and their symptoms. INTEGA is focused on positively impacting the lives of Canadians suffering from skin ailments by promoting healthy skin through clinically proven quality dermatology products. INTEGA strongly recognizes the importance of skin care: skin is the largest organ of the human body and its ailments impact both physical and psychological health. INTEGA believes that Canadian healthcare professionals and consumers require continued and additional access to quality and effective, scientifically-proven skincare products, and aims to fill the gaps present in the market.

IntelGen_x Corp.

IntelGenx

DAY 1 - May 2, 2016
15:30
Hall B

TSX.V: IGX, OTCQX: IGXT

IntelGenx is a leading drug delivery company focused on the development of innovative products based on its proprietary oral drug delivery technologies. Established in 2003, the Montreal-based company, listed on the TSX-V and OTC-QX, develops innovative oral drug delivery solutions based on its proprietary platform technologies, VersaFilm™, VersaTab™ and AdVersa™. IntelGenx has developed a broad and diverse product portfolio addressing unmet market needs and offering lifecycle management opportunities. Forfivo XL™, launched in 2012, is the first and only FDA approved once-daily bupropion HCl 450mg dose in a single tablet for the treatment of major depressive disorder. IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, clinical monitoring, IP protection, analytical method development and regulatory services. IntelGenx state-of-the art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to our clients.



Interface Biologics

DAY 1 - May 2, 2016
16:00
Hall A

Private

Interface Biologics is a commercial stage privately held company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices. IBI's primary technology focus areas are anti-thrombogenic devices that reduce thrombosis, anti-infective polymers, and programmable combination drug delivery devices. IBI's technology platforms include both surface modifying macro-molecules and biomedical polymer enabled drug delivery devices. IBI, a University of Toronto spinoff, is located at the MaRS Centre in Toronto, Canada.



Klox Technologies

DAY 1 - May 2, 2016
14:30
Hall A

Private

KLOX is a specialty pharmaceutical company focused on developing and commercializing products based on its proprietary BioPhotonic technology platform to address skin and soft tissue disorders. The company has a multi-franchise platform focusing on indications across Dermatology, Wound Care, and Oral Health.



Knight Therapeutics

DAY 1 - May 2, 2016
13:30
Hall C

TSX: GUD

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a publicly-traded, specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight Therapeutics Inc is focused on acquiring, in-licensing, selling and marketing innovative prescription and over-the-counter pharmaceutical products. Knight conducts late-stage clinical development on low risk, low expense product opportunities. All of Knight's products are sourced through partnerships.

LEAGUE

LEAGUE

Private

DAY 2 - May 3, 2016
9:30
Hall A

League (www.league.com) is a new digital health benefits platform that offers an alternative to traditional health insurance providers to SME's. With health insurance costs going up 130% over the last 10 years, and carriers delivering a product that employees increasingly don't love using, it's time for a change. League offers convenience and choice - an experience employees love, and savings for employers. Built on an end-end digital stack, League's platform connects employers, consumers and providers to provide an experience and cost structure advantage compared to traditional carriers. League offers its customers corporate wellness (entry point), personal spending accounts, health spending accounts (HSA/HRA), and group plans.



LED Medical Diagnostics

TSX-V: LMD, OTCQX: LEDIF

DAY 1 - May 2, 2016
10:30
Hall A

Founded in 2003 and headquartered in Burnaby, British Columbia, Canada, LED Medical Diagnostics Inc., through its wholly-owned subsidiaries LED Dental Inc. and LED Dental Ltd, provide dentists and oral health specialists with advanced diagnostic imaging products and software, in addition to the award-winning VELscope® Vx tissue fluorescence visualization technology. Backed by an experienced leadership team and dedicated to a higher level of service and support, LED Dental is committed to providing dental practitioners with the best technology available by identifying and adding leading products to its growing portfolio.



Medicago

Medicago

DAY 2 - May 3, 2016

14:00

Hall C

Private

Medicago is a clinical-stage biopharmaceutical company developing novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The company is committed to providing highly effective and competitive vaccines and therapeutic proteins based on its proprietary Virus-Like Particles (VLPs) and manufacturing technologies. This technology has the potential to offer vaccines and therapeutics with speed and cost advantages over competitive technologies, enabling the development of products for testing within approximately one month after the identification and reception of genetic sequences. This production time frame has the potential to rapidly vaccinate or treat populations and supply large volumes of products to the world market.



Medicenna Therapeutics

DAY 2 - May 3, 2016

14:00

Hall A

Private

Medicenna is a clinical stage, privately held, immuno-oncology company developing first-in-class, Interleukin-4 Empowered Cytokines™ (IL4-ECs) that specifically target the Interleukin-4 Receptor (IL4R). The IL4R is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor micro-environment (TME). Medicenna's IL4-ECs have the potential to not only purge the tumor but also un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients. Our lead IL4-EC, MDNA55 has been studied in 3 clinical trials in 72 patients with recurrent glioblastoma (rGBM), a uniformly fatal form of brain cancer, in which it has shown compelling indications of superior efficacy to the current standard of care. MDNA55 has been granted both, Fast Track (FDA) and Orphan Drug Status (FDA and EMA).



Medicure

DAY 2 - May 3, 2016
11:30
Hall B

TSX-V: MPH

Medicure is a specialty pharmaceutical company focused on the development and commercialization of therapeutics for the U.S. hospital market. The primary focus of the Company and its subsidiaries is the marketing and distribution of AGGRASTAT (tirofiban HCl) for non-ST elevation acute coronary syndrome in the United States, where it is sold through the Company's U.S. subsidiary, Medicure Pharma, Inc.



Merus Labs

DAY 1 - May 2, 2016
15:00
Hall C

TSX: MSL, NASDAQ: MSLI

Merus is a specialty pharmaceutical company engaged in the acquisition and licensing of pharmaceutical products. The Company utilizes its expertise in pharmaceutical markets and its access to capital to acquire and license niche branded products. Merus further enhances the sale and distribution of these products by the introduction of a focused marketing and promotion plan. The Company leverages its expertise and commercial platform in Europe, Canada and select other markets to deliver value.



newtopia™

Newtopia

DAY 2 - May 3, 2016
10:00
Hall A

Private

Newtopia is a personalized health company leveraging genetic testing and the latest engagement science to inspire individuals to make healthy lifestyle decisions. Newtopia's patented enterprise health engagement platform combines personality-matched coaching with mobile social health communities and genetically tailored health products to keep clients motivated and on track. Newtopia is partnering with insurers, employers and brands to offer disease prevention and management programs to risk-assessed individuals that deliver proven sustainable outcomes, quantifiable cost savings and a substantive ROI. Newtopia's programs and products are guideline and evidence-based and are available across the United States and Canada.



Nobilis Health

DAY 1 - May 2, 2016
10:30
Hall C

TSX: NHC, NYSE: HLTH

Nobilis is a full-service healthcare development and management company which currently owns or manages four surgical hospitals and five ASCs, partners with an additional thirty-three facilities throughout the country, and markets six independent brands. Deploying a unique patient acquisition strategy driven by direct-to-consumer marketing, Nobilis is focused on a specified set of procedures that are performed at our centers by local physicians.



Novadaq Technologies

DAY 2 - May 3, 2016
13:30
Hall B

TSX: NDQ, NASDAQ: NVDQ

Enabling medical professionals with clinically relevant, point-of-care imaging solutions to enhance the lives of patients and their caregivers, while reducing health care costs, is NOVADAQ's global mission. SPY fluorescence imaging technology provides surgeons with real-time visualization, leading to improved outcomes and reduced costs without exposing the patient to radiation. More than 150 peer-reviewed publications demonstrate that the use of SPY imaging technologies during complex surgery and diagnostic procedures, leads to lower rates of post-operative complications and lower hospital costs.



NuGeneris

DAY 1 - May 2, 2016
15:30
Hall C

Private

NuGeneris Specialty Pharmaceuticals Inc. is focused in the growing field of radiopharmaceuticals for personalized imaging and therapy. With two business units, the company's revenue growth from specialty products and contract services exceeds 25% annually, and NuGeneris is EBITDA positive. As Ontario's leading supplier of FDG (18F-Fluorodeoxyglucose) for PET imaging the company boasts a blue-ribbon list of hospital customers. Our specialized development and manufacturing services are attracting an increasing roster of international biopharmaceutical companies as clients. From production and distribution sites in Hamilton, Ottawa and Toronto, NuGeneris routinely ships products across North America and more recently into Europe. NuGeneris is seeking growth capital to expand its operations to take advantage of new product and customer opportunities.



Nuvo Pharmaceuticals

DAY 1 - May 2, 2016

14:00

Hall C

TSX: NRI

Nuvo is a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities. Nuvo has three commercial products that are available in a number of countries; Pennsaid 2%, Pennsaid and the heated lidocaine/tetracaine patch. Pennsaid 2% is sold in the U.S. by Horizon Pharma plc (NASDAQ:HZNP) and is available for partnering in certain other territories around the world. Nuvo manufactures Pennsaid for the global market and Pennsaid 2% for the U.S. market at its FDA, Health Canada and EU approved manufacturing facility in Varennes, Québec.



Oncolytics Biotech

DAY 1 - May 2, 2016

16:00

Hall B

TSX: ONC, OTCQX: ONCYF

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN®, its proprietary formulation of the human reovirus.



Parvus Therapeutics

DAY 2 - May 3, 2016
15:30
Hall A

Private

Parvus Therapeutics Inc. is a privately held biopharmaceutical company engaged in the development and commercialization of Navacim therapeutics, novel nanoparticle based immune complexes that induce the in-vivo expansion of disease-specific T- and B-regulatory cells resulting in the restoration of immune homeostasis. Navacims can be readily be tailored to target a broad range of autoimmune diseases and have the potential to radically improve the lives of patients suffering from these diseases.



Pediapharm

DAY 2 - May 3, 2016
14:00
Hall B

TSX-V: PDP

Pediapharm is the only Canadian specialty pharmaceutical company dedicated to serving the needs of the pediatric community. Its mission is to bring to the Canadian market the latest innovative pediatric products with the objective to improve the health and the well-being of children in Canada. Since its debut in 2008, Pediapharm has entered into numerous commercial agreements with partners from Canada and other countries around the world. The company's innovative product portfolio includes NYDA®; a breakthrough treatment for head lice; EpiCeram® a non-steroid emulsion for eczema; naproxen suspension, indicated to treat pain and inflammation due to various conditions, including Juvenile Idiopathic Arthritis; and a broad pipeline of products under registration.



Pharmascience

DAY 1 - May 2, 2016

14:30

Hall C

Private

Established in 1983, privately owned Pharmascience Inc. is the 3rd largest retail generic manufacturer and 10th largest pharmaceutical company in Canada, with a highly skilled workforce of 1,623 employees, 1,546 of which are Quebec-based. Pharmascience Inc. commercializes nearly 400 product families in 20 different dosage forms for over 2,000 products, including generic, branded prescription and over-the-counter consumer products. In Canada alone, more than 45 million prescriptions a year are filled with Pharmascience products. Additionally, Pharmascience has a significant international presence in 60 countries. Operationally, Pharmascience is fully integrated and controls all aspects of its operations, from R&D, through manufacturing to commercialization.



Profound Medical

DAY 1 - May 2, 2016

11:30

Hall A

TSX-V: PRN

Profound Medical is a Canadian medical device company that has commercialized a unique and minimally invasive procedure to ablate the prostate gland. Profound's novel technology combines real-time MR imaging with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control. It provides a highly precise treatment tailored to patient-specific anatomy and pathology. This method of prostate ablation offers short treatment times and low morbidity, allowing for fast patient recovery.



ProMetic Life Sciences

DAY 2 - May 3, 2016
13:30
Hall C

TSX: PLI, OTCQX: PFSCF

ProMetic Life Sciences Inc. is a long established biopharmaceutical company with globally recognized expertise in bioseparations, plasma-derived therapeutics and small-molecule drug development. ProMetic offers its state of the art technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order to develop best-in-class therapeutics and orphan drugs. ProMetic is also active in developing its own novel small-molecule therapeutic products targeting unmet medical needs in the field of fibrosis, anemia, neutropenia, cancer and autoimmune diseases/inflammation as well as certain nephropathies. Headquartered in Laval (Canada), ProMetic has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and commercial activities in the U.S., Canada, Europe, Russia, Asia and Australia.



Resverlogix

DAY 1 - May 2, 2016
11:30
Hall B

TSX: RVX

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with diseases such as high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, Alzheimer's disease, Orphan diseases, and peripheral artery disease, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials, currently in a Phase 3 trial BETonMACE in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL).



SEARCHLIGHT

PHARMA

Searchlight Pharma

DAY 2 - May 3, 2016
14:30
Hall B

Private

Searchlight Pharma aspires to become a leading Canadian-based specialty healthcare company through best-in class execution of the search, acquisition, commercialization, and focused development of innovative and unique specialty healthcare products that improve life-long human health and wellness. With a core focus on women's health, urology, sports medicine, and pediatrics, our team is committed to improving people's lives by bringing the right products to market.



SequenceBio

DAY 2 - May 3, 2016
16:00
Hall A

Private

SequenceBio is a biotechnology company leading a 100,000 person population sequencing initiative in the Province of Newfoundland & Labrador. The initiative will generate a uniquely powerful dataset of genomic and phenotypic information that SequenceBio will use for computational drug discovery and to empower better patient care. SequenceBio is committed to working with participants, collaborators and partners to enable innovation that enhances the lives of patients, families and communities in Newfoundland & Labrador and around the world.



Sophiris Bio

DAY 2 - May 3, 2016
16:00
Hall C

NASDAQ: SPHS

Sophiris Bio Inc. is a biopharmaceutical company developing topsalysin, a clinical-stage, targeted therapy for the treatment of urological diseases. Topsalysin is in Phase 3 clinical development for the treatment of the symptoms of benign prostatic hyperplasia (BPH) and is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. Topsalysin is also currently in a Phase 2a proof of concept study for the treatment of localized low to intermediate risk prostate cancer.



Synaptive Medical

DAY 1 - May 2, 2016
13:30
Hall A

Private

Synaptive Medical, a Toronto based company, has dedicated a talented team of engineers and scientists specifically to the development of neurosurgical technologies. The result is their BrightMatter™ Neurosurgical Products that provide advanced tools and information to allow surgeons to focus on patient outcomes. From advanced visualization and guidance to their first hands-free surgical scope, Synaptive medical is collaborating with surgeons, hospitals and industry partners to define a new standard of care for neurosurgical intervention.



Therapure Biopharma

DAY 1 - May 2, 2016

11:00

Hall C

Private

Therapure is a biopharmaceutical company focused on manufacturing complex biologics for its customers and on developing, manufacturing and selling its own blood and plasma-related therapeutic products. Its passion for quality and patient safety underpins everything it does in its three divisions: Therapure Biomanufacturing, an award-winning contract development and manufacturing division; Therapure Biologics, a division focused on using its proprietary PlasmaCap EBA™ technology to develop a portfolio of plasma-derived pharmaceutical products; and Therapure Innovations, a proprietary therapeutics and platform technologies research and development division. Therapure operates out of two facilities located in Mississauga: a 130,000 sq. ft. cGMP facility that includes biomanufacturing, research and quality control laboratories and is built to meet FDA (US), HPFB (Canada), EMA (Europe) and MHRA (UK) standards, and a new 43,000 sq. ft. facility housing 30,000 sq. ft. of cGMP warehouse.



Theratechnologies

DAY 2 - May 3, 2016

11:00

Hall B

TSX: TH

Theratechnologies is a specialty pharmaceutical company addressing unmet medical needs in metabolic disorders to promote healthy ageing and improved quality of life among HIV patients. Theratechnologies' leading product, EGRIFTA®, is available in Canada and in the United States.



Think Research

DAY 2 - May 3, 2016
10:30
Hall A

Private

Think Research Corporation (TRC) was founded in 2006 by Dr. Chris O'Connor, a practicing critical care physician at Trillium Health Centre. Since our founding, TRC has become the leading provider of digital order sets and clinical decision support tools in Canada. Our order sets and other clinical decision support tools are being used in more than 350 health care facilities across Canada, including province-wide implementations throughout Ontario, Saskatchewan, Prince Edward Island and Newfoundland & Labrador. Our clinical decision support tools are also being used internationally, in the United States and Europe.



TSO₃

DAY 1 - May 2, 2016
9:30
Hall A

TSX: TSO

Founded in 1998, TSO3 is committed to improving the standard of healthcare sterile reprocessing by providing breakthrough sterilization systems, related consumable supplies and accessories for heat-sensitive medical devices. TSO3 designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low-temperature sterilization processes currently used in hospitals. It also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes.



Titan Medical

DAY 1 - May 2, 2016
10:00
Hall A

TSX: TMD, OTCQX: TITXF

Titan Medical Inc. is a Canadian public company focused on the design and development of a robotic surgical system for application in minimally invasive surgery ("MIS"). The Company's SPORT™ Surgical System, currently under development, includes a surgeon-controlled robotic platform that incorporates a 3D high-definition vision system and multi-articulating instruments for performing MIS procedures through a single incision. The surgical system also includes a surgeon workstation that provides a surgeon with an advanced ergonomic interface to the robotic platform for controlling the instruments and provides a 3D high-definition endoscopic view of inside a patient's body. The SPORT™ Surgical System is designed to enable surgeons to perform a broad set of surgical procedures for general abdominal, gynecologic, and urologic indications.



Trillium Therapeutics

DAY 2 - May 3, 2016
11:00
Hall C

TSX: TR, NASDAQ: TRIL

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The Company's lead program, SIRPaFc, is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin. It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory ("do not eat") signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic ("eat") signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc (TTI-621) is ongoing. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. Stemming from this platform, the Company's most advanced preclinical program is an orally-available bromodomain inhibitor, followed by an epidermal growth factor receptor antagonist with increased uptake in the brain.



Triumvira Immunologics

DAY 2 - May 3, 2016
11:30
Hall A

Private

Triumvira Immunologics is a biotechnology company developing a novel platform for engineering T cells to attack cancers. Triumvira's innovative and proprietary technology for reprogramming T cells, called the T Cell-Antigen Coupler (or TAC), may possess advantages over other approaches to engineered T cells owing to the distinct biology and regulated activation of TAC-T cells. Triumvira has licensed the TAC technology from McMaster University in Hamilton, Ontario and its goal is to begin human testing of TAC T cells by the end of 2017.



Turnstone Biologics

DAY 2 - May 3, 2016
14:30
Hall A

Private

Turnstone Biologics Inc. is a biotechnology company focused on developing novel oncolytic viral immunotherapies for cancer. Turnstone's therapeutic platform is a first-in-class tumour-targeted oncolytic vaccine that combines potent tumour-killing effects of oncolytic viruses with the benefits of a cancer vaccine that harnesses the patient's own immune system to fight disease in a sustainable manner. The Company's platform leverages the innovations and expertise of its renowned founding scientists, Drs. John Bell, Brian Lichty and David Stojdl. Turnstone is also developing additional oncolytic virus strategies and immunotherapy combination treatments.



Vanrx PharmaSystems

DAY 1 - May 2, 2016
15:00
Hall A

Private

Vanrx Pharmasystems makes the most technologically advanced sterile filling solutions for the pharmaceutical industry. Vanrx fill-finish machines use isolated robotics and machine vision to automate the packaging of injectable drugs into nested vials, syringes or cartridges. The company was founded by pharmaceutical industry veterans to create the systems needed to make the next generation of innovative therapies.



VBI Vaccines

DAY 1 - May 2, 2016
13:30
Hall B

NASDAQ: VBIV

VBI Vaccines Inc. (“VBI”) is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. VBI’s eVLP vaccine platform allows for the design of enveloped (“e”) virus-like particle (“VLP”) vaccines that closely mimic the target virus. VBI’s lead eVLP asset is a prophylactic cytomegalovirus (“CMV”) vaccine; VBI has completed GMP manufacturing of its CMV candidate for use in formal preclinical and Phase I trials. VBI’s second platform is a thermostable technology that enables the development of vaccines and biologics that can preserve vaccine potency and withstand storage or shipment at fluctuating temperatures. VBI has completed proof of concept thermostability studies on a number of vaccine and biologic targets. VBI is headquartered in Cambridge, MA with research facilities in Ottawa, Canada.



Xenon Pharmaceuticals

DAY 2 - May 3, 2016
14:30
Hall C

NASDAQ: XENE

Xenon is a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications that it intends to commercialize on its own and for larger market indications that the company intends to partner with global pharmaceutical companies. Xenon has built a core enabling discovery platform, referred to as Extreme Genetics®, for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. Xenon's Extreme Genetics® platform has yielded the first approved gene therapy product in the European Union and a broad development pipeline and multiple pharmaceutical partnerships, including with Teva and Genentech.



Zymeworks

DAY 2 - May 3, 2016
9:30
Hall C

Private

Zymeworks is a privately held biotherapeutics company that is developing best-in-class Azymetric™ bi-specific antibodies and antibody drug conjugates for the treatment of cancer, autoimmune and inflammatory diseases. The company's novel Azymetric™, AlbuCORE™, and EFECT™ platforms, its Zymelink™ conjugation platform and cytotoxins, and its proprietary ZymeCAD™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies, multivalent protein therapeutics, and antibody drug conjugates across a range of indications. Zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations.

Bloom Burton exists to Accelerate Returns in Healthcare

The goal of all investors, companies and organizations is to achieve a monetizing event, such as the ability to raise capital, perform meaningful research and development, license or commercialize products, reach profitability or execute a strategic transaction.

The people who work at Bloom Burton have deep knowledge in medicine, science, patent and corporate law, finance and healthcare invention, development and commercialization.

The Bloom Burton team has been dedicated exclusively to the healthcare investment industry for more than a decade and, as a result of our deep knowledge and experience, our clients achieve a faster path to their monetizing events.

Bloom Burton works with institutional investors looking to invest in the healthcare sector. We also work with healthcare companies and organizations of all sizes and stages of development, who seek advice and capital.

As a result of our knowledge and experience in healthcare, we have developed a disciplined methodology for helping companies grow faster. Our methodology, and all of the services we offer, rest on six key pillars: deeper due diligence, a broader range of investment options, greater understanding of cross-border rules, relationships with international healthcare-specialized investors, engagement with the broader healthcare community, and a creative, tenacious, entrepreneurial culture.

Our Services

Our services help identify, cultivate and create investment opportunities in the healthcare sector, on behalf of companies and investors.

From start-ups through commercial launches, we are active in all areas of the healthcare industry, including biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services, healthcare IT, life science tools, animal health, nutrition and wellness.

Our six business services work cohesively to accelerate monetization for both company and investor clients:

Raising Capital and Financing

Mergers & Acquisition Advisory

Equity Research

Monetization Planning (Strategic and Scientific Consulting)

Direct Investment

Company Creation and Incubation

Let us know how we can help you accelerate your returns in the healthcare sector.

Sourcing capital to fund healthcare opportunities

From steering seed money to promising new life science ventures to facilitating private financing or raising public capital, Bloom Burton & Co. connects investors with attractive healthcare businesses poised for growth and profit.

As investment bankers, we nurture relationships between worthy companies and engaged investors who want to provide funding and participate in the growth of the healthcare sector.

Raise funding through a range of securities

We deal in the full range of securities to suit the capital requirements, or risk and return objectives, of companies and investors, from equity and debt issues to private placements or participating in selling groups of public offerings.

Garner attention of top fund managers

Our firm's unique professional relationships with international healthcare-specialized private and public fund managers has helped attract capital from around the world to Bloom Burton's issuer clients.

<p>Public Offering \$15,000,000</p>  <p>TITAN MEDICAL</p> <p>Units March 2016 Lead and sole bookrunner</p>	<p>Public Offering \$12,075,000</p>  <p>TITAN MEDICAL</p> <p>Units February 2016 Lead and sole bookrunner</p>	<p>Private Placement US \$15,000,000</p>  <p>ESSA</p> <p>January 2016 Financial Advisor</p>	<p>Private Placement US \$200 million</p>  <p>HLS Therapeutics Inc.</p> <p>Common Shares August 2015 Agent & Advisor</p>
<p>Syndicated Loan US \$185 million</p>  <p>HLS Therapeutics Inc.</p> <p>August 2015 Agent & Advisor</p>	<p>Public Offering USD \$55,200,000</p>  <p>TRILLIUM THERAPEUTICS INC.</p> <p>Common and Preferred Shares April 2015 Financial Advisor</p>	<p>Bought Deal \$27,370,000</p>  <p>CRH Medical CORPORATION</p> <p>Common Shares March 2015 Underwriter</p>	<p>Bought Deal \$100,000,000</p>  <p>knight</p> <p>Common Shares December 2014 Underwriter</p>

Enabling monetization through strategic transactions

The mergers and acquisitions advisory capability at Bloom Burton guides clients to conceptualize, structure and execute transactions to maximize returns and company performance.

Our team's professional expertise in healthcare and intellectual property also allows us to guide our clients with scientific and technical due diligence on their M&A opportunities and development strategies.

Guiding a broad range of M&A-type transactions

- Strategic Acquisitions
- Sales & Divestitures
- Spinoffs & Splitoffs
- Strategic Partnerships
- Reorganization & Restructuring
- Leveraged Buyouts
- Takeover Defenses and Proxy Contests
- Special Committee Assignments
- Fairness/Valuation Opinions

M&A Transaction
US \$148,000,000

 Acquires 

To Form



February 2016
Advisor to Tribute

M&A Transaction
\$47,000,000




Completes acquisition of




November 2015
Financial Advisor to Alveda

M&A Transaction
\$25,000,000



Completes acquisition of



June 2015
Financial Advisor to
Medical Futures

M&A Transaction
USD \$73,000,000



Completes acquisition of

**Gastroenterology
Anesthesia
Associates, LLC**

December 2014
Financial Advisor to CRH

Asset Sale
USD \$45,000,000



Acquires Pennsaid® 2% US



October 2014
Exclusive Financial Advisor
to Nuvo

M&A Transaction
Approx. \$357,000,000




acquires majority stake in



September 2013
Advisor to Medicago
Management

M&A Transaction
Approx. \$13,000,000



completes acquisition of



August 2013
Advisor to Thallion

M&A Transaction
Approx. \$510,000,000



completes acquisition of



December 2012
Advisor to YM BioSciences

Influential opinions and insights on companies

Our equity analysts ask the right questions, dig deeper for answers and find details others miss. Our research division covers key Canadian healthcare companies to understand how they operate, recognize their relative strengths and weaknesses, and determine the impact of clinical and commercial developments and competitive events.

Specialized equity research that gets attention

Our analysts make influential buy, sell and hold recommendations in healthcare and biotechnology, gather industry knowledge, and provide insightful market intelligence to help guide our investor clients.

Charting what's new in biotech: Our Canadian Healthcare Roadmap Publication

Our Canadian Healthcare Roadmap report, published twice a year, is essential reading for institutional investors to track drugs and medical products in development or being commercialized by public healthcare companies, as well as milestones that could impact share performance.

Distribution of healthcare research

Bloom Burton's research products are disseminated simultaneously to all our customers who are authorised to receive them. Request to be added to Bloom Burton's equity research distribution list. Email Brian Bloom at bbloom@bloomburton.com.

Research Coverage

Aralez Pharmaceuticals **(TSX: ARZ, NASDAQ:ARLZ)**

Arbutus Biopharma **(NASDAQ:ABUS)**

Aurinia Pharmaceuticals **(TSX:AUP, NASDAQ:AUPH)**

BELLUS Health **(TSX:BLU)**

Cardiome Pharma **(TSX:COM, NASDAQ:CRME)**

Concordia Healthcare **(TSX:CXR)**

CRH Medical **(TSX:CRH, NYSE MKT:CRHM)**

ESSA Pharma **(TSX:EPI, NASDAQ:EPIC)**

Knight Therapeutics **(TSX:GUD)**

Trillium Therapeutics **(TSX:TR, NASDAQ:TRIL)**

Helping realize the value of innovations

Understanding the business opportunities to bring healthcare advances to market, and how to successfully utilize them, are key to any company's commercial and financial success. It is also key to investor returns.

Our management consulting practice provides capital market advice, plus scientific, clinical and medical insight to help innovative companies position themselves to profit from their good ideas and achieve a monetizing event. We structure our work as either defined projects or long-term arrangements.

Why companies and investors come to us

We speak with large companies and investors every day, and we know what they are looking for. We are therefore the ideal group to help our companies plan their capital market strategies, investigate the relevance of new biological pathways, and consider new therapeutic indications and clinical designs, catalogue and diligence new products or companies for acquisition.

<p>Valuation Opinion</p>  <p>October 2015</p>	<p>Strategic Advisory</p>  <p>August 2015</p>	<p>Scientific Advisory</p>  <p>January 2015</p>	<p>Scientific Advisory</p>  <p>January 2015</p>
<p>Strategic Advisory</p>  <p>October 2014</p>	<p>Scientific Advisory</p> <p>Ontario-based Research University</p> <p>May 2014</p>	<p>Capital Markets & Scientific Advisory</p>  <p>March 2014</p>	<p>Scientific Advisory</p>  <p>September 2013</p>

Maximizing opportunities in healthcare investing

Through our affiliate Bloom Burton Investment Group, we consult with and offer our extensive knowledge and experience in the healthcare industry to Stratigis Capital Advisors Inc., the manager of the following three investment products which provide investors the opportunity to invest in a diversified portfolio of healthcare companies:

Bloom Burton Canadian Healthcare Fund LP

The Bloom Burton Canadian Healthcare Fund exists to achieve superior returns by investing primarily in equity and equity-linked securities of publicly traded Canadian healthcare and biotechnology companies. The Fund invests in companies of all capitalization sizes with a focus on the biotechnology, emerging pharmaceutical, medical device, diagnostic and healthcare service industries. The manager employs fundamental, bottom-up quantitative analysis and a qualitative research methodology to identify mispriced securities or assets in a market in which Bloom Burton has unique insights, respected experience and long-standing relationships.

Bloom Burton Healthcare Structured Lending Fund I and II LP and Bloom Burton Healthcare Lending Trust

The Bloom Burton Healthcare Structured Lending I and II LP Funds and the Bloom Burton Healthcare Lending Trust exist to achieve superior returns for investors by targeting a specialized niche in the fund market that is overlooked by other lenders. The Fund and the Trust provide debt or debt-like capital to emerging commercial-stage Canadian healthcare companies with assets and cash-flow to support debt, but seeking funding amounts not provided by traditional lenders. The Fund and the Trust invest in both privately held and publicly traded companies using a variety of structures.

For additional information relating to these investment products, please contact Stratigis Capital Advisors Inc. at +1 416 368 6002 or info@stratigis.ca

Establishing new opportunities in healthcare

In very special situations, instead of providing services for cash fees, Bloom Burton partners with entrepreneurs and researchers to form and incubate new companies, in exchange for a founding equity position. Bloom Burton leverages all of its services and skills:

- Advise on the company's corporate and capital structure;
- Catalog and select the best target indications based on commercial, competitive and scientific considerations;
- Design the optimal international patent strategy;
- Design preclinical and clinical programs to produce valuable evidence for financing and partnering;
- Support the optimal regulatory strategy;
- Advise on the identification, license or acquisition of complimentary intellectual property and assets;
- Recruit the best management team and Board to help execute the Company's strategy;
- Create marketing materials to inform, engage and transact with investors and partners;
- Raise seed and subsequent private and public capital; and
- Leverage the entire Bloom Burton platform to increase the exposure of the Company.



The Cross-Border Biotech Blog

Bloom Burton and its network of healthcare industry veterans publish regular pieces on the state of Biotech, Pharma, Med Tech and Healthcare IT in Canada and the US. Here is a selection from the past year:

LOOKING INSIDE THE BIOTECH BLACK BOX

A deeper look into various topics of drug development by Wayne Schnarr.

- Market Exclusivity – Product Life-Cycle Management
- Market Exclusivity – Regulatory Data
- Market Exclusivity – Patents

GUEST EDITORIAL

An invited guest blog on healthcare investment and company growth.

- Beyond Borders: Keeping your business investor friendly - by Mark Smith
- Cross-border merger and acquisition: 5 tips for a successful deal - by Sonia Yung

APOLLO SHRUGGED

TALES FROM THE CANADIAN PHARMA INDUSTRY

A modern view on drug adherence by Stephen Nicolle.

- Can technology improve patient adherence?
- On being unintentionally non-adherent

Q2 SHARE PRICE PERFORMANCE IN 2015 THE CANADIAN PART 2 HEALTHCARE SECTOR

Detailed quarterly reviews of share price performance in the Canadian healthcare industry by Wayne Schnarr.

To read more, subscribe online at www.bloomburton.com/blog

OUR PEOPLE

EXECUTIVES



Brian Bloom
Co-Founder, President and
Head of Institutional Sales



Jolyon Burton
Co-Founder, CEO and Head
of Investment Banking



Armand Balboni JD, PhD
Director

INVESTMENT BANKING



Michael Pollard MBA, CFA
Vice President, Investment
Banking



John Holyoake DPhil
Vice President, Investment
Banking



Evelyn Pau PhD
Associate, Investment
Banking



James Rowland MSc
Associate, Investment
Banking



Claudia Hui PhD
Analyst, Investment Banking



Vincent Nadeau PhD
Analyst, Investment Banking



Chi Liu
Analyst, Investment Banking



EQUITY RESEARCH



David Martin PhD, MBA
Managing Director and Head
of Equity Research



Antonia Borovina PhD
Associate, Equity Research

INSTITUTIONAL SALES



Andrew Duckman
Vice President, Institutional
Sales

CORPORATE STAFF



Ann McIntosh
Chief Compliance Officer



Stephanie Mazzone CPA, CA
Controller




Erika Agnew
Senior Administrator

CONFERENCE MAP



Bloom Burton & Co.
Healthcare Investor Conference
May 2-3, 2016



- 1. BALLROOM WEST
- 2. BALLROOM CENTRE
- 3. BALLROOM EAST (LARGE)
- 4. BALLROOM EAST
- 5. VIDEO
- 6. VIDEO AREA

- 7. SHERATON HALL E
- 8. SHERATON HALL F
- 9. SHERATON HALL D
- 10. OSGOOD FOYER
- 11. SHERATON HALL A
- 12. SHERATON HALL B

- 13. SHERATON HALL C
- 14. OSGOOD BALLROOM WEST
- 15. OSGOOD BALLROOM EAST

LOWER CONCOURSE

OUR SPONSORS

We gratefully acknowledge the support of our sponsors

GOLD SPONSORS



BAKER & MCKENZIE



BDO



Blakes



EY
Building a better
working world



JLT



Johnson & Johnson INNOVATION
— JLABS —



mccarthy
tetrault



NATIONAL | Equicom



The Horwood Team



RICHARDSON GMP



TRINITY
Underwriting



TROUTMAN
SANDERS

SILVER SPONSOR



TMX | Toronto Stock Exchange | TSX Venture Exchange | TSX Private Markets



We are proud to announce

THE INAUGURAL
BLOOM BURTON
AWARD GALA

2017

To celebrate the most
extraordinary contribution to the
Canadian healthcare sector